{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kendra KL"],"funding":["U.S. Department of Health & Human Services | NIH | National Cancer Institute","NCI NIH HHS"],"pagination":["272-282"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12948668"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(2)"],"pubmed_abstract":["The phase 2 SWOG S1512 trial ( NCT02775851 ) was designed to evaluate the response to pembrolizumab (anti-PD-1) in individuals with desmoplastic melanoma. Here we report the results of cohort A of the trial, evaluating the pathological complete response (pCR) rate of neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma. Secondary endpoints included clinical response rate, overall survival and toxicities. Twenty-eight eligible individuals with resectable desmoplastic melanoma received intravenous pembrolizumab (200 mg) every 3 weeks three times, followed by excision. Tissue samples before treatment, at 3-5 weeks after treatment initiation and at the time of surgery were reviewed. The primary endpoint of pCR rate by local pathological review was 71% (95% confidence interv"],"journal":["Nature cancer"],"pubmed_title":["Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial."],"pmcid":["PMC12948668"],"funding_grant_id":["R35 CA197633","P01 CA244118"],"pubmed_authors":["Ribas A","Khushalani NI","Plaza JA","Contreras CM","Brohl AS","Wu MC","Chen JM","Gonzalez CR","Vega-Crespo A","Norman K","Baselga-Carretero I","Sondak VK","Eroglu Z","Ikeguchi A","Chmielowski B","Carson WE","Hu-Lieskovan S","Patel SP","Sharon E","Grossmann KF","Wada DA","In GK","Kendra KL","Bellasea SL","Campbell KM","Hyngstrom J","Markowitz J","Monroe M","Bowles T","Deen NNA","Medina E","Garcilazo IP","Moon J"],"additional_accession":[]},"is_claimable":false,"name":"Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.","description":"The phase 2 SWOG S1512 trial ( NCT02775851 ) was designed to evaluate the response to pembrolizumab (anti-PD-1) in individuals with desmoplastic melanoma. Here we report the results of cohort A of the trial, evaluating the pathological complete response (pCR) rate of neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma. Secondary endpoints included clinical response rate, overall survival and toxicities. Twenty-eight eligible individuals with resectable desmoplastic melanoma received intravenous pembrolizumab (200 mg) every 3 weeks three times, followed by excision. Tissue samples before treatment, at 3-5 weeks after treatment initiation and at the time of surgery were reviewed. The primary endpoint of pCR rate by local pathological review was 71% (95% confidence interv","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T23:35:48.643Z","creation":"2026-07-12T03:11:21.608Z"},"accession":"S-EPMC12948668","cross_references":{"pubmed":["41611998"],"doi":["10.1038/s43018-025-01113-y"]}}